IN190792B - - Google Patents

Info

Publication number
IN190792B
IN190792B IN2797DE1998A IN190792B IN 190792 B IN190792 B IN 190792B IN 2797DE1998 A IN2797DE1998 A IN 2797DE1998A IN 190792 B IN190792 B IN 190792B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Nabil Hanna
Gary Ronald Braslawsky
Kandasamy Hariharan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of IN190792B publication Critical patent/IN190792B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2797DE1998 1997-09-18 1998-09-17 IN190792B (US06559137-20030506-C00112.png)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93335997A 1997-09-18 1997-09-18

Publications (1)

Publication Number Publication Date
IN190792B true IN190792B (US06559137-20030506-C00112.png) 2003-08-23

Family

ID=25463798

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2797DE1998 IN190792B (US06559137-20030506-C00112.png) 1997-09-18 1998-09-17

Country Status (19)

Country Link
US (4) US20010018054A1 (US06559137-20030506-C00112.png)
EP (1) EP1015031A4 (US06559137-20030506-C00112.png)
JP (1) JP2001516727A (US06559137-20030506-C00112.png)
KR (1) KR100540267B1 (US06559137-20030506-C00112.png)
CN (1) CN1234413C (US06559137-20030506-C00112.png)
AR (1) AR013012A1 (US06559137-20030506-C00112.png)
AU (1) AU742216B2 (US06559137-20030506-C00112.png)
CA (1) CA2303178A1 (US06559137-20030506-C00112.png)
CO (1) CO4790100A1 (US06559137-20030506-C00112.png)
HK (1) HK1033653A1 (US06559137-20030506-C00112.png)
IL (2) IL134937A0 (US06559137-20030506-C00112.png)
IN (1) IN190792B (US06559137-20030506-C00112.png)
MY (1) MY131805A (US06559137-20030506-C00112.png)
NO (1) NO20001413L (US06559137-20030506-C00112.png)
RU (1) RU2219947C2 (US06559137-20030506-C00112.png)
SA (1) SA98190719B1 (US06559137-20030506-C00112.png)
TW (1) TWI252108B (US06559137-20030506-C00112.png)
WO (1) WO1999013912A1 (US06559137-20030506-C00112.png)
ZA (1) ZA988461B (US06559137-20030506-C00112.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU4724401A (en) * 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
US7244232B2 (en) * 2001-03-07 2007-07-17 Biomed Solutions, Llc Process for identifying cancerous and/or metastatic cells of a living organism
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
JP5452835B2 (ja) 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるIgMの産生とその定量方法
AP2007003869A0 (en) 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
US7957931B2 (en) * 2005-12-23 2011-06-07 Gcoder Systems Ab Positioning pattern
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
BRPI0711193A2 (pt) * 2006-05-05 2013-06-18 Transtech Pharma Inc proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
CA2703585A1 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
KR20110139292A (ko) 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
AU2010305374A1 (en) * 2009-10-09 2012-05-03 Sanofi Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
RU2013127625A (ru) * 2010-11-18 2014-12-27 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
WO2013078286A1 (en) * 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP3188716B1 (en) 2014-09-03 2022-10-26 GeneSegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
SI3628049T1 (sl) 2017-05-04 2023-10-30 Acceleron Pharma Inc. Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
CN112119157A (zh) 2018-03-06 2020-12-22 宾夕法尼亚大学董事会 前列腺特异性膜抗原car及其使用方法
CN114814223A (zh) * 2022-04-20 2022-07-29 昆明市妇幼保健院 一种用于监测及控制疟原虫治疗的系统及设备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052A (en) * 1845-05-13 Tktjss
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents

Also Published As

Publication number Publication date
NO20001413D0 (no) 2000-03-17
JP2001516727A (ja) 2001-10-02
RU2219947C2 (ru) 2003-12-27
AR013012A1 (es) 2000-11-22
NO20001413L (no) 2000-05-18
MY131805A (en) 2007-09-28
CO4790100A1 (es) 1999-05-31
AU9565898A (en) 1999-04-05
CN1234413C (zh) 2006-01-04
WO1999013912A1 (en) 1999-03-25
AU742216B2 (en) 2001-12-20
IL134937A0 (en) 2001-05-20
SA98190719B1 (ar) 2006-08-06
KR20010024109A (ko) 2001-03-26
CA2303178A1 (en) 1999-03-25
EP1015031A1 (en) 2000-07-05
CN1279616A (zh) 2001-01-10
IL134937A (en) 2008-04-13
KR100540267B1 (ko) 2006-01-10
ZA988461B (en) 1999-03-30
US6998125B2 (en) 2006-02-14
US20010019715A1 (en) 2001-09-06
US20060153848A1 (en) 2006-07-13
US20010018054A1 (en) 2001-08-30
US20040137014A1 (en) 2004-07-15
EP1015031A4 (en) 2004-03-17
TWI252108B (en) 2006-04-01
HK1033653A1 (en) 2001-09-14

Similar Documents

Publication Publication Date Title
BE2018C032I2 (US06559137-20030506-C00112.png)
IN190792B (US06559137-20030506-C00112.png)
CH0944937H2 (US06559137-20030506-C00112.png)
ITVE970021A0 (US06559137-20030506-C00112.png)
BE2013C047I2 (US06559137-20030506-C00112.png)
ITPD970084A0 (US06559137-20030506-C00112.png)
ITPD970104A0 (US06559137-20030506-C00112.png)
ITPD970144A0 (US06559137-20030506-C00112.png)
ITTO970448A0 (US06559137-20030506-C00112.png)
BR9700653A (US06559137-20030506-C00112.png)
BR9701757A (US06559137-20030506-C00112.png)
CN3053500S (US06559137-20030506-C00112.png)
CN3056276S (US06559137-20030506-C00112.png)
CN3057613S (US06559137-20030506-C00112.png)
CN3055603S (US06559137-20030506-C00112.png)
CN3058057S (US06559137-20030506-C00112.png)
CN3055471S (US06559137-20030506-C00112.png)
CN3055389S (US06559137-20030506-C00112.png)
CN3055179S (US06559137-20030506-C00112.png)
CN3055123S (US06559137-20030506-C00112.png)
CN3054902S (US06559137-20030506-C00112.png)
CN3054556S (US06559137-20030506-C00112.png)
CN3054162S (US06559137-20030506-C00112.png)
CN3054099S (US06559137-20030506-C00112.png)
CN3058025S (US06559137-20030506-C00112.png)